AKT1 and hepatocellular carcinoma: Both sorafenib and lenvatinib, used for HCC treatment, inhibit VEGFR-mediated signalling and carnitine transporters, which may suppress signalling in the downstream PI3k/Akt/mTOR pathway, leading to subsequent skeletal muscle mass loss [30].